LATEST NEWS
Latest News
Latest News
THE OPHTHALMOLOGY MEDICINES COMPANY
Kodiak Sciences is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases
OUR MISSION
Kodiak aims to prevent and treat the leading causes of blindness in the developed world
TRAILBLAZING SCIENCE
OUR CREATIVE AND THOUGHTFUL FOUNDATION
“GO-TO” MEDICINES
OUR CHALLENGE TO THE STATUS QUO
SINGULAR FOCUS IN OPHTHALMOLOGY
OUR 24/7/365
OUR PRODUCT CANDIDATES
We intend to progress our portfolio of late-phase clinical assets across a broad spectrum of retinal diseases as rapidly as we can into Phase 3 value inflection points
Tarcocimab Tedromer
High-prevalence retinal
vascular diseases
Wet AMD
Diabetic retinopathy
Retinal vein occlusion
Phase 3
KSI-501
High-prevalence retinal
vascular diseases
Indications of interest include wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy
Phase 3
KSI-101
Macular edema
secondary to inflammation
Phase 1b
Tarcocimab tedromer
Tarcocimab tedromer
Anti-VEGF ABCD
Anti-VEGF ABCD
Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine. With tarcocimab’s signature durability and safety record, as demonstrated in multiple studies, we believe tarcocimab could be differentiated in the market as a longest-acting biologic based on its Antibody Biopolymer Conjugate Drug (ABCD) Platform design.
Our objective is to finish the clinical development program and enable the marketing application. We intend to do this using the enhanced formulation of conjugated and unconjugated forms that we believe balances towards durability without compromising immediacy. Learn more
Tarcocimab is our most advanced program. We have important learnings from six pivotal studies across four major retinal diseases and maintain our conviction that tarcocimab could be an important medicine. With tarcocimab’s signature durability and safety record, as demonstrated in multiple studies, we believe tarcocimab could be differentiated in the market as a longest-acting biologic based on its ABCD Platform design. Our objective is to finish the clinical development program and enable the marketing application. Learn more
KSI-501
KSI-501
Bispecific anti-IL-6, VEGF trap ABCD
Bispecific anti-IL-6, VEGF trap ABCD
KSI-501 is first-in-class bispecific Antibody Biopolymer Conjugate Drug (ABCD) designed to address the opportunity for improved efficacy with extended durability in high-prevalence retinal vascular diseases by targeting retinal inflammation and vascular permeability simultaneously.
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases. Learn more
The pathophysiology of retinal vascular and hyperpermeability disorders is multifactorial. In addition to VEGF-mediated fluid and leakage, IL-6 stimulates defective angiogenesis, is implicated in anti-VEGF treatment resistance, and is associated with disease progression in high-prevalence retinal diseases.
KSI-501 is a first-in-class, anti-IL-6, VEGF trap bispecific antibody biopolymer conjugate built on our Antibody Biopolymer Conjugate Drug (ABCD) platform and is being developed for high-prevalence retinal vascular diseases to address the unmet needs of targeting multiple biologies and extended durability. Learn more
KSI-101
KSI-101
Bispecific anti-IL-6, VEGF trap protein
Bispecific anti-IL-6, VEGF trap protein
KSI-101 is a potent 100 mg/mL high-strength bispecific protein being developed for the treatment of macular edema secondary to inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying disease mechanisms of IL-6-mediated inflammation and edema, and VEGF-mediated vascular permeability. Learn more
KSI-101 is a novel bispecific protein targeting IL-6 and VEGF for the treatment of macular edema associated with inflammation.
Currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. We believe that KSI-101 has the potential to meaningfully help patients with retinal fluid and inflammation by being a first-in-class biologic that addresses the underlying mechanisms of disease. Learn more
THE ABCD OF OUR SCIENCE
We are bringing new science to the design and development of next generation retinal medicines. Our Antibody Biopolymer Conjugate Drug (ABCD) Platform uses a bio-inspired polymer to enable multi-modal, multi-mechanistic treatment of complex ocular and systemic diseases
Antibody Biopolymer Conjugate Drug
- Designed-in durability
- Designed to target multiple intracellular and extracellular mechanisms simultaneously
- Designed for ocular and systemic diseases
OUR CULTURE AND VALUES
We are actively building a place, our Kodiak Village, where we are inspired, where we feel valued, and where we can grow our personal and professional journeys while advancing our mission. Historically referred to within Kodiak as the 4 C’s, our values are:
CURIOSITY
Staying fresh.
Asking why.
Being naturally inquisitive.
CREATIVITY
A safe place to think outside the box.
A focus on how to solve the problem.
COMPASSION
For ourselves.
For our colleagues.
For our patients.
COURAGE
Saying no when that’s the right answer.
Saying yes when that’s the right answer.
Regardless.
WORKING AT KODIAK
We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas.
